Loading organizations...
§ Private Profile · Newton, MA, USA
Biotechnology company developing regenerative therapies using hydrogels for vision restoration, targeting Geographic Atrophy and stem cell therapies.
Based in Cambridge, Massachusetts, GelMEDIX is a biotechnology company developing regenerative therapies and photo-crosslinked hydrogels designed to restore vision in patients suffering from ocular diseases. The organization focuses specifically on ophthalmology treatments, advancing a lead cell therapy for Geographic Atrophy alongside a next-generation hydrogel platform engineered for stem cell-derived applications. To support its clinical and technological development, the enterprise has secured $13 million in seed financing backed by a syndicate of investors that includes Safar Partners, HTL Biotechnology, and Beacon Angels. In addition to its venture capital backing, the firm recently established a strategic development partnership with an undisclosed global pharmaceutical company to further advance its proprietary stem cell-derived therapies. While the exact founding year remains undisclosed, the company's foundational hydrogel technology was originally developed by researchers Professor Nasim Annabi and Professor Reza Dana.
GelMEDIX has raised $13.0M across 1 funding round.
GelMEDIX has raised $13.0M in total across 1 funding round.
GelMEDIX has raised $13.0M across 1 funding round. Most recently, it raised $13.0M Seed in February 2026.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 17, 2026 | $13M Seed | Safar Partners | Beacon Angels, Boston Harbor Angels, HTL Biotechnology, TIE Angels Boston | Announced |
GelMEDIX has raised $13.0M in total across 1 funding round.
GelMEDIX's investors include Safar Partners, Beacon Angels, Boston Harbor Angels, HTL Biotechnology, TiE Angels Boston.